Comprehensive Psychiatry
Volume 51, Issue 2 , Pages 165-170 , March 2010

The relationship between depressive symptoms and subjective well-being in newly admitted patients with schizophrenia

References 

  1. Zisook S, McAdams LA, Kuck J, Harris MJ, Bailey A, Patterson TL, et al. Depressive symptoms in schizophrenia. Am J Psychiatry. 1999;156:1736–1743
  2. Siris SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157:1379–1389
  3. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J. Depression in first-episode schizophrenia. Am J Psychiatry. 1993;150:1643–1648
  4. Subotnik KL, Nuechterlein KH, Asarnow RF, Fogelson DL, Goldstein MJ, Talovic SA. Depressive symptoms in the early course of schizophrenia: relationship to familial psychiatric illness. Am J Psychiatry. 1997;154:1551–1556
  5. Wassink TH, Flaum M, Nopoulos P, Andreasen NC. Prevalence of depressive symptoms early in the course of schizophrenia. Am J Psychiatry. 1999;156:315–316
  6. Siris SG, Bench C. Depression and schizophrenia. In:  Hirsch SR,  Weinberger DR editor. Schizophrenia. Oxford: Blackwell Publishing; 2003;p. 142–167
  7. Azorin JM. Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand Suppl. 1995;91:20–23
  8. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183–190
  9. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology. 1998;8:671–679
  10. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry. 1998;43:803–810
  11. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology. 1999;20:491–505
  12. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51:171–180
  13. Sim K, Mahendran R, Siris SG, Heckers S, Chong SA. Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression. Psychiatry Res. 2004;129:141–147
  14. Hansson L. Determinants of quality of life in people with severe mental illness. Acta Psychiatr Scand Suppl. 2006;429:46–50
  15. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008;98:201–208
  16. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(Suppl 3):133–138
  17. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology. 2002;162:3–10
  18. de Haan L, Weisfelt M, Dingemans PM, Linszen DH, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics Scale and the Subjective Deficit Syndrome Scale. Psychopharmacology. 2002;162:24–28
  19. Naber D, Riedel M, Klimke A, Vorbach EU, Lambert M, Kühn KU, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand. 2005;111:106–115
  20. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(Suppl 2):5–17
  21. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A, Wagner T, et al. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry. 2006;67:1690–1697
  22. Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, Alamir S, et al. Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv. 2002;53:1319–1321
  23. Lambert M, Holzbach R, Moritz S, Postel N, Krausz M, Naber D. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders. Int Clin Psychopharmacol. 2003;18:251–260
  24. Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG, Fleischhacker WW. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand. 2007;116:354–361
  25. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Press; 1994;
  26. Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50:79–88
  27. Kluge M, Wehmeier PM, Dittmann RW, Langer F, Czekalla J, Lehmann M, et al. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry. 2005;38:6–12
  28. de Haan L, Nimwegen L, Amelsvoort T, Dingemans P, Linszen D. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41:125–128
  29. Karow A, Moritz S, Lambert M, Schoder S, Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology. 2005;38:320–326
  30. Yoon JS, Kook SH, Lee HY, Lee C, Paik IH. The development of a Korean modification of the scale to measure Subjective Well-Being Under Neuroleptic Treatment (SWN). J Korean Neuropsychiatr Assoc. 2000;39:987–998
  31. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–276
  32. Bell MD, Lysaker PH, Beam-Goulet JL, Milstein RM, Lindenmayer JP. Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Res. 1994;52:295–303
  33. Whitehorn D, Brown J, Richard J, Rui Q, Kopala L. Multiple dimensions of recovery in early psychosis. Int Rev Psychiatry. 2002;14:273–283
  34. Good KP, Whitehorn D, Rui Q, Milliken H, Kopala LC. Olfactory identification deficits in first-episode psychosis may predict patients at risk for persistent negative and disorganized or cognitive symptoms. Am J Psychiatry. 2006;163:932–933
  35. Beck AT, Ward CH, Mendelson M, Mock J, Erbauch J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–571
  36. Beck AT. Depression: clinical, experimental, and theoretical aspects. New York: Harper & Row; 1967;
  37. Hahn HM, Yum TH, Shin YW, Kim KH, Yoon DJ, Chung KJ. A standardization study of Beck Depression Inventory in Korea. J Korean Neuropsychiatr Assoc. 1986;25:487–502
  38. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177–183
  39. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology. 2004;171:121–132
  40. Inada T, Yagi G, Miura S. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res. 2002;57:227–238
  41. Kim JH, Jung HY, Kang UG, Jeong SH, Ahn YM, Byun HJ, et al. Metric characteristics of the DIEPSS: a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17:1354–1359
  42. Inada T, Beasley CM, Tanaka Y, Walker DJ. Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol. Int Clin Psychopharmacol. 2003;18:39–48
  43. Kim JH, Cho SY, Byun HJ, Kang UG, Ahn YM, Kim YS. Multidimensional sensory phenomena in antipsychotic-induced akathisia. J Clin Psychopharmacol. 2004;24:618–623
  44. Fleischhacker WW, Rabinowitz J, Kemmler G, Eerdekens M, Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry. 2005;187:131–136
  45. Hofer A, Kemmler G, Eder U, Edlinger M, Hummer M, Fleischhacker WW. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65:932–939
  46. Galletly CA, Clark CR, McFarlane AC, Weber DL. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res. 1997;72:161–166
  47. Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann. 1988;11:51–62
  48. Liddle PF, Barnes TR, Curson DA, Patel M. Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand. 1993;88:243–247
  49. Bermanzohn PC, Porto L, Arlow PB, Pollack S, Stronger R, Siris SG. Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophr Bull. 2000;26:517–525
  50. Liddle PF, Barnes TR. The subjective experience of deficits in schizophrenia. Compr Psychiatry. 1988;29:157–164
  51. de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatry. 2004;49:290–296
  52. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry. 1993;(Suppl):39–44
  53. Addington D, Addington J, Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res. 1994;11:239–244
  54. Rocca P, Bellino S, Calvarese P, Marchiaro L, Patria L, Rasetti R, et al. Depressive and negative symptoms in schizophrenia: different effects on clinical features. Compr Psychiatry. 2005;46:304–310
  55. Siris SG, Addington D, Azorin JM, Falloon IR, Gerlach J, Hirsch SR. Depression in schizophrenia: recognition and management in the USA. Schizophr Res. 2001;47:185–197
  56. Fitzgerald PB, Williams CL, Corteling N, Filia SL, Brewer K, Adams A, et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr Scand. 2001;103:387–392
  57. Ruggeri M, Bisoffi G, Fontecedro L, Warner R. Subjective and objective dimensions of quality of life in psychiatric patients: a factor analytical approach: the South Verona Outcome Project 4. Br J Psychiatry. 2001;178:268–275
  58. Trauer T, Duckmanton RA, Chiu E. A study of the quality of life of the severely mentally ill. Int J Soc Psychiatry. 1998;44:79–91
  59. Lobana A, Mattoo SK, Basu D, Gupta N. Quality of life in schizophrenia in India: comparison of three approaches. Acta Psychiatr Scand. 2001;104:51–55
  60. Wehmeier PM, Kluge M, Schacht A, Helsberg K, Schreiber W. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178–186
  61. Moritz S, Krausz M, Gottwalz E, Lambert M, Perro C, Ganzer S, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology. 2000;33:48–51
  62. Naber D, Karow A. Good tolerability equals good results: the patient's perspective. Eur Neuropsychopharmacol. 2001;11(Suppl 4):S391–S396
  63. Kim JH, Kim SY, Ahn YM, Kim YS. Subjective response to clozapine and risperidone treatment in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:301–305
  64. Weiden P, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297–310
  65. Voruganti LN, Awad AG. Personal Evaluation of Transitions in Treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res. 2002;56:37–46

PII: S0010-440X(09)00066-2

doi: 10.1016/j.comppsych.2009.05.004

Comprehensive Psychiatry
Volume 51, Issue 2 , Pages 165-170 , March 2010

Article Tools